Biomarin Pharmaceutical (BMRN) Non-Current Debt (2025 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Non-Current Debt came in at $1.4 billion in Q1 2026, up 139.51% on a QoQ basis from $597.2 million in Q4 2025.
Powered by 
Analysis
Biomarin Pharmaceutical (BMRN) Non-Current Debt (2025 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 2 years of Non-Current Debt data on file, last reported at $1.4 billion in Q1 2026.
- Quarterly Non-Current Debt changed N/A year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (changed N/A YoY) and the FY2025 annual result came in at $597.2 million, changed N/A from the prior year.
- Non-Current Debt rose to $1.4 billion in Q1 2026, from $597.2 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $1.4 billion in Q1 2026 to a low of $597.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Biomarin Pharmaceutical | 12.88 Bn | 12.01 Bn | 786.91 Mn | 4.19 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.19 Bn |
| Mar 31, 2026 | 1.43 Bn |
| Dec 31, 2025 | 597.18 Mn |